How high is too high? Valuations continue to climb for Canadian cannabis businesses

As more cannabis companies go public and private businesses raise capital at an unprecedented clip, valuations have become a hot topic among industry observers, insiders and investors.

That’s especially true in Canada, where a growing number of cannabis firms have fetched multibillion-dollar valuations in the public markets as they’ve hustled to become a top player in the nation’s impending adult-use market.

“With cannabis in Canada, it’s a horse race right now,” said Patrick Rea, co-founder and CEO of CanopyBoulder, a Colorado-based cannabis-focused business accelerator. “Investors are asking ‘Who’s in front? I’m going to put money on that guy.’”

After its trading debut on the Nasdaq last week, British Columbia-based Tilray has a market cap in excess of $3 billion – more than 140 times its reported 2017 revenue of $20.5 million.

Tilray joins a growing list of Canada’s largest licensed cannabis producers that have gleaned generous appraisals from the public markets:

  • Canopy Growth, which is traded on the Toronto Stock Exchange as WEED, has a market cap of roughly 7 billion Canadian dollars ($5.3 billion), with fiscal year 2018 revenue of CA$77.9 million.
  • Aurora Cannabis (TSE: ACB) has a market cap of CA$4 billion, with 2017 revenue of CA$31.1 million.
  • Aphria (TSE: APH) has a market cap of CA$2.4 billion, with 2017 revenue of CA$20.4 million.

Across the board, the market caps ring in at multiples of nearly 90 to more than 120 times each of the firms’ reported revenues.

To be sure, the market has already experienced a significant falloff. The Canadian Marijuana Index peaked at about CA$40 billion in early January and has since fallen to about CA$20 billion.

“It is not unusual for an early stage, hypergrowth industry to receive high valuations,” said Scott Greiper, president at Viridian Capital Advisors.

Looking back at tech and other emerging industries, Greiper said it’s common for early stage markets to be valued on an “enterprise value to revenue multiple” – a metric used for high-growth businesses that don’t have a long history of positive earnings.

“This stage of market growth is all about market share, early revenue traction and an overall land grab,” he said.

But even given those considerations: “In the Canadian marketplace, valuations certainly seem excessive.”

How long those sky-high valuations might stick around remains to be seen, said Alan Brochstein, founder of 420 Investor, a Houston-based firm that advises interested cannabis investors.

“If you just look at the Canadian market, you’re going to struggle to justify the valuations that you’re seeing right now,” Brochstein said. “Without being critical, that’s a warning signal to investors.

“But valuations are hard in new industries for a number of reasons – and nobody knows the future.”

Betting on a future beyond Canada

By 2022, sales of legal cannabis in Canada are projected to grow to nearly $6 billion.

Even at that level, the Canadian market will be eclipsed by what could become an $18 billion-$22 billion industry in the United States, according to projections from the Marijuana Business Factbook 2018.

In part, it’s the market potential beyond Canada’s borders that’s luring investors to bet big on Canadian cannabis. They’re considering the advantages these firms have to be among the biggest and first to scale globally.

Across Canada, cannabis companies have used their rich balance sheets to gobble up rivals and acquire assets in foreign markets, including Latin America and Europe.

“The Canadian market – where the adult-use market will only be as big as California – does not have enough market potential to support the valuations currently given,” said Nick Kovacevich, CEO of California-based cannabis packing company Kush Bottles.

“Because of this, we are now seeing a rise in the number of Canadian companies aggressively moving internationally, a key advantage they have over U.S. companies.

“These international moves help open the market potential and allow those Canadian firms to justify their valuations.”

While it may be easier for Canadian firms to go global, Brochstein cautioned that much of that work lies ahead.

“The reality is, scaling up globally takes a lot of capital and a lot of partnerships,” he said. “It’s not an endeavor that is easily accomplished.”

Bubble ahead?

Still, such growth potential could keep the generous valuations coming, industry insiders say.

In the U.S., Canadian cannabis companies buying up takeout targets and spinning off assets into new companies are poised to grow their market share as more states legalize, said Derek Peterson, CEO of Terra Tech, a vertically integrated MJ business with operations in California and Nevada.

“The influx of institutional capital into the space is resulting in consolidation in multiple marketplaces, and because of the limited amount of permits that exist, holders of those permits are experiencing a significant rise in their value,” he said.

The rising values “don’t necessarily mean that there is a bubble,” Kovacevich said. “For a bubble to occur it would mean that the valuations are getting higher than the market potential.

“With the ultimate U.S. market potential so big and new states coming online, I think there is room for loftier valuations.”

While the Canadian valuations “seem excessive,” Viridian’s Greiper said investment rationale in the space generally continues to be supported by strong fundamentals, including:

  • The acceleration of cannabis industry sales and the pace of marijuana legalization on a global scale.
  • The growing number of public cannabis companies in the U.S. and Canada that have been embraced by the capital markets – providing increased liquidity for marijuana stocks and investors.
  • The gradual acceptance by major exchanges in the U.S., including the Nasdaq and New York Stock Exchange, in listing cannabis companies.
  • Advanced technology being adopted by cannabis companies driving economies of scale, lower production costs and more efficient operations.

Harder to predict: Just when the market will begin to “shake out,” Greiper said.

When that finally begins to happen, investors will then begin valuing companies based on more typical metrics, such as EBITDA, operating income and cash flow.

For now, however, the race is on to be an early market leader.

“We’re at a moment in time where the interest is incredibly high – and investors are buying into that future potential based on who appears to be winning today,” CanopyBoulder’s Rea said.

Lisa Bernard-Kuhn can be reached at [email protected]

6 comments on “How high is too high? Valuations continue to climb for Canadian cannabis businesses
  1. Bill Shane on

    If the values are so high, why have stock prices on companies like Aurora and Aphria been dropping for the past 6 weeks? I can understand a correction of fantasy vs. reality, but that correction took place about 3 months ago. It’s all very confusing.

    Reply
  2. William Fowler on

    These poor investors obviously have not had any knowledge of ridiculous multiples and capitalization rates; otherwise they would not be investing in such ventures. The guys forming the IPO’s will be making the money and the investors holding the bag of empty air, once the market adjusts itself to real life economics. I have been a valuation expert for 30 years and only during the dot-com bubble were such high valuations, of course the market adjusted. Most CPA’s do not know valuation theory so investors are at a loss to know true value for what they are buying…Investors would be better off gaming in Vegas, at least they will have fun losing their money…

    Reply
    • Al on

      Are these multiples not based on sales, which have not really started happening other than for medical marijuana? We need to see how the sales will look once the adult market, and potentially the edibles and drinks start affecting sales. Especially as world demand escalates.

      Reply
  3. Brett Roper on

    Canada has had the good fortune of having federal support which I suspect is at the heart of these valuation metrics (access to banking and investment capital) … they also have federal support for legalization beyond medical which, this position having been known since later last year has also provided a positive boost for such valuations (Constellation investment in Canopy as one such example).

    I still believe that similar to several US based maturing marketplace examples (Colorado, Oregon, Washington, to name a few) of such volatility, the Canadian marketplace will experience similar heartburn down the road as the Canadian Cannabis landscape better defines itself through competition and maturity.

    It is abundantly clear that with the known or prognosticated 10’s of millions of SF of dedicated space noted by the current LP’s playing in the space, only the low cost producers with the best quality products will survive in the long term and as Canada still has no legal ‘edible’ products in play (a year or more in the distance according to most with knowledge) they will be behind in one of the fastest growing aspects of the Cannabusiness landscape. This may be one reason the larger LP’s are ‘raiding’ the US brands marketplace at present.

    With wholesale gram price pressures only the truly efficient operators will thrive as we have seen elsewhere.

    Reply
  4. Brett Roper on

    One more thing in that some provinces have recently agreed to or indicated interest in outdoor cultivation, this metric will certainly change the dynamic of things over time as we have already seen in Oregon this past year.

    Reply
  5. Brian Truax on

    William being a “valuation expert” it strikes me as unusual that apparently you have little knowledge of basic private equity investing. Enjoy your next trip to Vegas but there is a difference between gambling and investing who knew.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *